Skip to content

Eeffect of Nebulized hypertonic saline solution on treatment of infant with viral bronchiolitis

Comparison of the efficacy of Nebulized 3% hypertonic saline solution and 0.9% normal saline in2-24 m/o children with acute bronchiolitis.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT138903134096N1
Enrollment
60
Registered
2013-08-12
Start date
2008-09-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Viral bronchiolitis. Acute bronchiolitis

Interventions

Intervention 1: In intervention group, nebulized 3% hypertonic saline 3 cc per 10 min till 3 dose, then countinue Q8h if patient addmited. Intervention 2: In control group, standard treatment with neb
Treatment - Other
In intervention group, nebulized 3% hypertonic saline 3 cc per 10 min till 3 dose, then countinue Q8h if patient addmited.
In control group, standard treatment with nebulized 0.9% saline 3cc Q10 min till 3 dose, then continue Q8h if patient admitted.

Sponsors

Vice Chancellor of Research, Bushehr University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 2 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: a total of infant (2 month to 24 month of age )with mild to moderate bronchiolitis seen in aliasghar tertiary care pediatric center ED in 2008-2010(fall & winter)were randomized to double blind treatment with nebulized salbutamol in either 3% saline or 0.9% saline. bronchiolitis: first or second episodes of respiratory distress with wheezing or sign of viral respiratory tract infections includes RR>60; 38c=T; PR>180 or coryza. Exclusion criteria: pre-exiting cardiac or pulmonary disease; previous diagnosis of asthma or positive familial history of asthma; previous history of prematurity(GA60; 38c=T; PR>180 second or more episodes of respiratoye distress.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Change in sum of RADI score and YALE clinical score. Timepoint: at first & 30 minute later. Method of measurement: physical examination.;Admission rate. Timepoint: 30 minute. Method of measurement: physical examination.

Secondary

MeasureTime frame
Intravenous fluid use. Timepoint: 14 days. Method of measurement: physical examination.;Length of stay. Timepoint: day of discharge. Method of measurement: physical examination.;Oxygen use. Timepoint: day of discharge. Method of measurement: physical examination.;Remission of cough and wheezing. Timepoint: 1 mounth. Method of measurement: physical examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Gissou Hatami

Bushehr University of Medical Sciences

gissoo_hat@yahoo.com, hatami@bpums.ac.ir+98 77 1252 0657

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026